Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: Comparison with reference dose risperidone, 6 mg/day


Autoria(s): Meltzer, Herbert Y.; Elkis, Helio; Vanover, Kimberly; Weiner, David M.; van Kammen, Daniel P.; Peters, Perry; Hacksell, Uli
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

14/10/2013

14/10/2013

2012

Resumo

Most atypical antipsychotic drugs (APDs), e. g. risperidone (RIS), produce more extensive blockade of brain serotonin (5-HT)(2A) than dopamine (DA) D-2 receptors. This distinguishes them from typical APDs, e.g. haloperidol (HAL). Our objective was to test the hypothesis that augmentation of low doses of RIS or HAL (2 mg/day) with pimavanserin (PIM), a selective 5-HT2A inverse agonist, to enhance 5-HT2A receptor blockade, can achieve efficacy comparable to RIS, 6 mg/day, but with lesser side effects. In a multi-center, randomized, double-blind, 6 week trial, 423 patients with chronic schizophrenia experiencing a recent exacerbation of psychotic symptoms were randomized to RIS2mg + placebo (RIS2PBO), RIS2mg + PIM20mg (RIS2PIM), RIS6mg + PBO (RIS6PBO), HAL2mg + PBO (HAL2PBO), or HAL2mg + PIM20mg (HAL2PIM). Improvement in psychopathology was measured by the PANSS and CGI-S. The reduction in PANSS Total Score with RIS2PIM at endpoint was significantly greater than RIS2PBO: -23.0 vs. -16.3 (p = 0.007), and not significantly different from the RIS6PBO group: -23.2 points. The percentage of patients with >= 20% improvement at day 15 in the RIS2PIM group was 62.3%, significantly greater than the RIS6PBO (42.1%; p = 0.01) and the RIS2PBO groups (37.7%; p = 0.002). Weight gain and hyperprolactinemia were greater in the RIS6PBO group than the RIS2PIM group but there was no difference in extrapyramidal side effects (EPS). HAL2PBO and HAL2PIM were not significantly different from each other in efficacy but HAL2PIM had less EPS at end point. Both HAL groups and RIS6PBO showed equal improvement in psychopathology at endpoint, indicating HAL 2 mg/day is effective to treat an acute exacerbation in chronic schizophrenia patients. In conclusion, a sub-effective RIS dose combined with PIM to enhance 5-HT2A receptor blockade provided faster onset of action, and at endpoint, equal efficacy and better safety, compared to standard dose RIS. These results support the conclusion that 5-HT2A receptor blockade is a key component of the action of some atypical APDs and can reduce EPS due to a typical APD. (C) 2012 Elsevier B.V. All rights reserved.

BioLIne Rx

BioLIne Rx

Cephalon

Cephalon

Dainippon Sumitomo

Dainippon Sumitomo

Eli Lilly

Eli Lilly

EnVivo

EnVivo

Janssen

Janssen

Otsuka

Otsuka

Pfizer

Pfizer

Sunovion

Sunovion

Fapesp

FAPESP

Novartis and Roche

Novartis and Roche

Identificador

SCHIZOPHRENIA RESEARCH, AMSTERDAM, v. 141, n. 41335, supl. 1, Part 2, pp. 144-152, NOV, 2012

0920-9964

http://www.producao.usp.br/handle/BDPI/34386

10.1016/j.schres.2012.07.029

http://dx.doi.org/10.1016/j.schres.2012.07.029

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

AMSTERDAM

Relação

SCHIZOPHRENIA RESEARCH

Direitos

closedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #SCHIZOPHRENIA #PIMAVANSERIN #5-HT2A #RISPERIDONE #HALOPERIDOL #ANTIPSYCHOTIC #EXTRAPYRAMIDAL #WEIGHT GAIN #ATYPICAL ANTIPSYCHOTIC-DRUGS #RECEPTOR INVERSE AGONIST #DOUBLE-BLIND PET #SCHIZOPHRENIC-PATIENTS #TARDIVE-DYSKINESIA #SCHIZOAFFECTIVE DISORDER #DOPAMINE-D-2 RECEPTORS #NEUROLEPTIC THRESHOLD #COGNITIVE IMPAIRMENT #ANTAGONIST M100907 #PSYCHIATRY
Tipo

article

original article

publishedVersion